SoftBank Vision Fund 2, a venture capital fund, led a $75m Series C round in Big Health, a digital therapeutics company, with participation from ArrowMark Partners, Octopus Ventures, Gilde Healthcare, Kaiser Permanente Ventures, and Morningside Ventures. “Although studies show that three-quarters of people prefer a non-drug approach to mental health care, the vast majority of mental health patients today receive medications, often associated with substantial risk of harm or side effects. Our digital therapeutics offer an equitable, safe, and effective non-drug alternative at a huge scale, and our products are backed by leading clinical evidence, with more than 28,000 participants across our clinical studies. With strong commercial partnerships, including the ability to bill through the PBM, we now have the rails in place to improve health outcomes at an enormous scale. We are proud to announce our Series C funding, which will further fuel our growth and the mass adoption of digital therapeutics,” Peter Hames, Big Health Co-Founder and Chief Executive Officer.